Compare NXL & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXL | NVNO |
|---|---|---|
| Founded | 2010 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.8M |
| IPO Year | 2022 | 2017 |
| Metric | NXL | NVNO |
|---|---|---|
| Price | $4.82 | $10.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 116.6K | 15.3K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $301,647.00 | $31,243.00 |
| Revenue This Year | $15.52 | N/A |
| Revenue Next Year | $100.00 | $140.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 78.78 | N/A |
| 52 Week Low | $0.22 | $0.30 |
| 52 Week High | $7.69 | $13.44 |
| Indicator | NXL | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 70.21 | 53.08 |
| Support Level | $0.41 | $9.96 |
| Resistance Level | $7.69 | $11.40 |
| Average True Range (ATR) | 0.48 | 0.73 |
| MACD | 0.30 | 0.03 |
| Stochastic Oscillator | 65.06 | 62.91 |
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.